Homepage Contact
International Society for Cellular Medicine
Mainbar
Spacer GIF
Spacer GIF

About ISCM
>> Mission Statement
>> Statutes
>> Board
>> Support Us

Laboratory Research
>> Cardiovascular Disease
>> Cancer
>> Other Research

Research Archive
>> Cellular Health Research
>> Studies Worldwide

Health News
>> Natural Health
>> Business With Disease
>> Other News
>> News Archive

World Health
>> Who is WHO?
>> Stop Codex!
>> Defend DSHEA
>> Health for All

Welcome Message

The International Society for Cellular Medicine is a worldwide cooperation of physicians, scientists, health practitioners and students for the dissemination of natural health information. The ISCM is dedicated to natural health research worldwide.

>> Read our Mission Statement
>> Read our Statute
 

Laboratory Research
Laboratory ResearchPublications of the worlds leading institute for research of the health benefits of vitamins, amino acids, minerals and their synergistic properties .
>> Cardiovascular Disease
>> Cancer
>> Other Research
>> Scientific Presentations

Research Archive
Research ArchiveScientific breakthroughs that have been presented at numerous conferences of American and European health associations and published in medical journals worldwide.
>> Cellular Health Research
>> Studies Worldwide

World Health
World Health The worldwide struggle of alternative medicine against the pharmaceutical business with disease - and why people have to take health into their own hands.
>> Who is WHO?
>> Stop Codex!
>> Defend DSHEA
>> Health For All

What's New

Safety Vs. Efficacy
Last week, investors in biotech Biogen Idec got a taste of the biggest risk in the pharmaceutical business: unexpected side effects. After one death due to an apparent side effect, Biogen and partner Elan pulled their multiple sclerosis drug Tysabri, which had been approved with rapid speed by the Food and Drug Administration only four months before. It was the most recent of several drug safety dilemmas.
>> Read article at Forbes.com

Pfizer Stirs Concern With Plans to Sell Heart Drugs Only as Pair
A drug that could be one of the most promising new heart treatments in a decade is generating controversy even before it is approved, because its maker, Pfizer, plans to sell it only in combination with the company's best-selling cholesterol treatment, Lipitor.
>> Read article at NYTimes.com

Find out more here:
>> Natural Health
>> Business With Disease
>> Other News
>> News Archive

Spacer GIFSitemap
Sitemap